Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

doi:10.1186/1471-2407-6-247

Research article

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

Dirk Vordermark^*, Klemens Ruprecht, Peter Rieckmann, Wolfgang Roggendorf, Giles H Vince, Monika Warmuth-Metz, Oliver Kölbl and Michael Flentje

* Corresponding author: Dirk Vordermark vordermark_d@klinik.uni-wuerzburg.de

BMC Cancer 2006, 6:247 doi:10.1186/1471-2407-6-247

No comments have yet been made on this article.

BMC Cancer

Viewing options

Associated material

Tools

Share this article

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

BMC Cancer

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Share this article

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)